UroGen Pharma Appoints New CMO and Board Member
Ticker: URGN · Form: 8-K · Filed: 2024-09-13T00:00:00.000Z
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
TL;DR
UroGen Pharma shakes up leadership with a new CMO and board member.
AI Summary
UroGen Pharma Ltd. announced on September 12, 2024, changes in its executive team and board of directors. Specifically, Dr. Elizabeth O'Farrell has been appointed as the new Chief Medical Officer, and Ms. Jennifer McNevey has joined the Board of Directors. These appointments are effective immediately.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or focus, potentially impacting its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- Dr. Elizabeth O'Farrell (person) — Appointed Chief Medical Officer
- Ms. Jennifer McNevey (person) — Appointed to Board of Directors
- September 12, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Elizabeth O'Farrell has been appointed as the new Chief Medical Officer.
Who has joined the Board of Directors?
Ms. Jennifer McNevey has joined the Board of Directors.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 12, 2024.
What is UroGen Pharma Ltd.'s primary business sector?
UroGen Pharma Ltd. is in the Pharmaceutical Preparations sector (SIC code 2834).
What is the company's principal executive office address?
The address of the principal executive offices is 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
Filing Stats: 409 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2024-09-13 16:15:54
Filing Documents
- d851871d8k.htm (8-K) — 22KB
- 0001193125-24-218868.txt ( ) — 140KB
- urgn-20240912.xsd (EX-101.SCH) — 3KB
- urgn-20240912_lab.xml (EX-101.LAB) — 18KB
- urgn-20240912_pre.xml (EX-101.PRE) — 11KB
- d851871d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 13, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer